Development of carbonic anhydrase IX-targeting molecular-targeted photodynamic therapy
Kazuki Miura1, Hiroyuki Nakamura1
1Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8501, Japan.
Abstract:
The efficacy of molecular-targeted photodynamic therapy (MT-PDT) targeting carbonic anhydrase (CA) IX, a cancer-specific molecule, was demonstrated. CA ligand-directed photosensitizers 1-3 were evaluated for their ability to deactivate CAIX protein in cells. Compounds 2 and 3 selectively deactivated CAIX protein under 540 nm light without affecting internal standard proteins. Mechanistic studies revealed that compound 3 not only induced CAIX-selective light inactivation via singlet oxygen but also induced cell membrane damage, resulting in an anti-tumor effect. In vivo studies of CAIX-targeting MT-PDT revealed that treatment with compound 3 followed by light irradiation exhibited remarkable anti-tumor activity, leading to tumor degeneration and necrosis.
Insights
Molecular-targeted photodynamic therapy (MT-PDT) effectively targets carbonic anhydrase IX (CAIX) in cancer. Compound 3 demonstrated significant anti-tumor effects by selectively deactivating CAIX and damaging cancer cell membranes.
Area of Science:
- Biochemistry
- Oncology
- Photochemistry
Background:
- Carbonic anhydrase (CA) IX is a cancer-specific protein.
- Molecular-targeted photodynamic therapy (MT-PDT) offers a promising approach for cancer treatment.
- Targeting CA IX with photosensitizers can lead to selective cancer cell destruction.
Purpose of the Study:
- To evaluate CA ligand-directed photosensitizers for their ability to deactivate CA IX protein.
- To investigate the anti-tumor efficacy of MT-PDT targeting CA IX.
- To elucidate the mechanism of action for CA IX-targeted MT-PDT.
Main Methods:
- Synthesis and evaluation of CA ligand-directed photosensitizers.
- In vitro studies assessing CA IX protein deactivation under specific light wavelengths.
- In vivo studies to determine anti-tumor activity of MT-PDT.
Main Results:
- Compounds 2 and 3 selectively deactivated CA IX protein under 540 nm light.
- Compound 3 induced CA IX-selective light inactivation via singlet oxygen and cell membrane damage.
- In vivo MT-PDT with compound 3 showed remarkable anti-tumor activity, causing tumor degeneration and necrosis.
Conclusions:
- CA IX-targeting MT-PDT is an effective strategy for cancer treatment.
- Compound 3 exhibits potent anti-tumor effects through selective CA IX deactivation and membrane damage.
- Further development of CA IX-targeted MT-PDT holds significant therapeutic potential.
